WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

NCT07330050 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)

Interventions

BIOLOGICAL: Whole Agonist-Stimulated T (WAST) cells injection
DRUG: Docetaxel

Sponsor

Tianjin Medical University Cancer Institute and Hospital